Skip to main content
#
AWHONN

Join/Renew
our facebook page instagram
HomeAWHONN MN Logo WearAWHONN NationalAnnual ConferenceJoin/RenewMN Section LeadersNetworking GroupResourcesContact
2021 Conference Sponsor: Prolacta Bioscience

Supplementing mother’s own milk (MOM) with the first and only commercially available human milk–based fortifier made from 100% human donor milk instead of cow milk

Mission

Prolacta Bioscience develops clinically proven, high-value products derived from human milk that are designed to meet the needs of extremely premature infants in the neonatal intensive care unit.

Vision

Established in 1999, Prolacta Bioscience is a privately held life sciences company that has touched the lives of more than 63,000 premature infants globally.
 

As we work to bring life-saving nutrition to critically ill and premature infants, we’re also committed to ethical business practices, protecting the safety of our team, and fostering an inclusive culture. Prolacta is the world’s leading hospital provider of 100% human milk–based nutritional products. Available to hospitals since 2006, our fortifiers changed the standard of care for extremely premature infants worldwide and remain the first and only nutritional fortifiers made from 100% donor milk instead of cow milk. We are also exploring the therapeutic potential of human milk including applications for infants who need surgery for congenital cardiac and gastrointestinal disorders.

Relevant Products

Clinically proven, human milk–based nutrition

More than 63,000 premature infants throughout the world have experienced proven clinical benefits from Prolacta’s 100% human milk–based nutritional products1.

  • Improve health outcomes2,3,4,5,6,7 including:
    • Bronchopulmonary dysplasia (BPD)8,9,5,6
    • Late-onset sepsis8,5,7
    • Retinopathy of prematurity (ROP)8,5,6
    • Necrotizing enterocolitis (NEC)6,2,5

When used as part of an Exclusive Human Milk Diet (EHMD) as compared to cow milk–based fortifiers, Prolacta’s products are clinically proven to:

  • Improve growth10
  • Reduce feeding intolerance6
  • Lower mortality and morbidity3,4,5
  • Shorten neonatal intensive care unit (NICU) stays5,6

Reduce hospital costs511

Additional Info (events, notices, updates)

Free CE’s available on demand on our website.

For More Information

Diane Strauss
phone: 612-599-9323    
email: 
dstrauss@prolacta.com

prolacta.com

Site Powered By
    wave3websites.com
    Online web site design